Friday, April 18, 2025
Media Contact:
Gail Ellis | Editorial Communications Coordinator | 405-744-9152 | [email protected]
Article provided by The University of Arkansas.
Exploring the Impact of GLP-1 Weight-Loss Drugs on Food and Beverage Preferences
Are weight-loss medications like **Mounjaro, Ozempic, and Wegovy** changing the way we eat? According to a recent study by the **Arkansas Agricultural Experiment Station**, it’s a resounding yes! As an increasing number of individuals embrace these **GLP-1 agonists** for weight loss, they are reporting striking shifts in their eating habits, particularly a decrease in the consumption of processed foods and sugary beverages. This has sent ripples through the food and beverage industry, with companies rapidly adjusting their strategies to meet evolving consumer preferences.
Food Industry on Alert
“We’ve seen a paradigm shift in the marketing strategies employed by food companies,” stated **Brandon McFadden**, a professor and the Tyson Endowed Chair in food policy economics at the University of Arkansas. With declining stock prices for packaged food companies and a surge in pharmaceutical companies manufacturing these weight-loss drugs, the battle for consumer attention is fiercer than ever.
The Research Overview
Led by graduate student **Andrew Dilley**, this groundbreaking study aimed to gauge how GLP-1 drugs are influencing food choices across various demographics. The team, which included several post-doctoral researchers and renowned academic **Jayson Lusk**, sought to provide valuable insights into the changing landscape of food consumption.
“Our findings reveal that the adoption of GLP-1 agonists significantly alters the quantity and types of food that people are drawn to,” Lusk highlighted. With a potential explosion in GLP-1 usage, the repercussions for food companies could be profound. As demand for processed foods dwindles, opportunities will arise for fresh fruits and vegetables as a healthier alternative.
Understanding GLP-1s
What exactly are GLP-1 drugs? Since receiving **FDA approval** for weight loss prevention, their usage skyrocketed by **300% from 2020 to 2022**. Originally designed to aid those with diabetes, these drugs mimic the body’s natural GLP-1 hormone, which reduces appetite and enhances insulin production following meals. The outcome? Significant weight loss, often exceeding **15%** in clinical trials.
As of 2024, thousands are estimated to start using GLP-1s weekly, with over half of the U.S. population potentially qualifying for a prescription. With obesity affecting approximately **42%** of American adults, the demand for effective weight-loss solutions has never been higher.
The Specifics of Weight Management
GLP-1s are prescribed for adults with a body mass index (BMI) of **30 or higher**, or those with a BMI of **27 or higher** who also suffer from weight-related health conditions. The current FDA-approved medications include **Saxenda, Wegovy, Ozempic, Zepbound**, and **Monjaro**.
Consumption Trends: What’s on the Decline?
Findings from the study indicate a remarkable trend: **current and former GLP-1 users reported a notable reduction** in their consumption of various foods and beverages. Approximately **70%** of respondents acknowledged consuming **less processed food**, while **50%** reported lower intake of **soda, refined grains,** and **beef**. In fact, there were additional decreases in the consumption of starchy vegetables, pork, alcohol, fruit juice, and dairy milk.
Interestingly, while foods such as chicken, coffee, fish, seafood, nuts, eggs, plant-based meat, whole grains, and plant-based milk also experienced slight dips (ranging from **10% to 25%**), the overwhelming preference leaned towards healthier options. **Fresh fruits, leafy greens, and water** were among the few categories with increased consumption.
Desires vs. Reality
Despite the noted declines, many GLP-1 users expressed a lingering **interest in processed foods, sodas,** and **beef**—a testament to the complex relationship between appetite and choice. This study serves as a stark reminder that even as habits are changing, the allure of familiar cravings remains strong.
The comprehensive survey analyzed responses from **1,955 participants**, with distinguished segments including current GLP-1 users, those who had previously used them, prospective users, and individuals not planning to use these medications.
Future Directions
To further explore these dynamics, McFadden indicated that the results could aid in crafting effective communication strategies as well as enhancing product positioning for the food industry. A follow-up study focusing on the adverse effects of GLP-1s is already underway, paving the way for further research in this burgeoning field. The study, titled “Characteristics and food consumption for current, previous, and potential consumers of GLP-1s,” was published in the journal **Food Quality and Preference** in March.
As the landscape of food consumption continues to evolve, the interplay between health, appetite, and choice will undoubtedly shape our culinary future. It remains to be seen how the food industry will innovate in response to the demands of an increasingly health-conscious consumer base, but one thing is certain: the era of GLP-1s has only just begun.
Mention of product names does not imply endorsement by the University of Arkansas System Division of Agriculture. The study was partly supported by the Tyson Endowed Chair in Food Policy Economics.
